Sofosbuvir Approved for Marketing Phase N/A Trials for Post-transplant Hepatitis C

IndicationsStatusPurposePhase
Approved for MarketingNot AvailableNot Available
clinicaltrials.gov IdentifierTitleDrugs
NCT01779518Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C